Clinical Trial Detail

NCT ID NCT04185311
Title Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Jonsson Comprehensive Cancer Center
Indications

triple-receptor negative breast cancer

Her2-receptor negative breast cancer

Therapies

Ipilimumab + Nivolumab + Talimogene laherparepvec

Age Groups: adult senior

No variant requirements are available.